Tamrintamab pamozirine
Modify Date: 2024-07-17 21:53:32
Tamrintamab pamozirine structure
|
Common Name | Tamrintamab pamozirine | ||
|---|---|---|---|---|
| CAS Number | 2148334-68-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Tamrintamab pamozirineTamrintamab pamozirine (DC-1728001; SC-003; SC-003 ADC) an Antibody-Drug Conjugate (ADC) targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab pamozirine can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab pamozirine can be used in ovarian cancer research.[1]. |
| Name | Tamrintamab pamozirine |
|---|
| Description | Tamrintamab pamozirine (DC-1728001; SC-003; SC-003 ADC) an Antibody-Drug Conjugate (ADC) targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab pamozirine can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab pamozirine can be used in ovarian cancer research.[1]. |
|---|---|
| Related Catalog | |
| Target |
Dipeptidase 3 (DPEP3, MBD3)[1] |
| In Vitro | Tamrintamab pamozirine can be cleaved to pyrrolobenzodiazepine (PBD) dimers to specifically bind DPep3-expressing cells. After internalization, the release of PBD warheads through degradation of the antibody component lysosome induces cytotoxicity[2]. |
| In Vivo | Tamrintamab pamozirine (single dose) induced tumor regression in DPEP3-positive HGSC transplantation models (PDX), including platinum-resistant PDX models. Moreover, the antitumor effect of Tamrintamab pamozirine is mediated by a significant reduction in the frequency of tumor-originating cells (TIC)[2]. |
| References |
| No Any Chemical & Physical Properties |